Valneva SE (VALN) Total Debt (2020 - 2026)
Valneva SE (VALN) posted Total Debt of $213.5 million for Q1 2026, up 2.35% sequentially from $208.6 million in Q4 2025, and up 12.01% YoY from $190.6 million in Q1 2025.
Valneva SE (VALN) Total Debt (2020 - 2026) Analysis & Trends
Valneva SE has reported Total Debt for 7 years, with the latest figure at $213.5 million in Q1 2026.
- Quarterly Total Debt rose 12.01% year-over-year to $213.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $213.5 million (up 12.01% YoY) and the FY2025 annual result came in at $208.6 million, up 2.84% from the prior year.
- Total Debt rose to $213.5 million in Q1 2026 per VALN's latest filing, from $208.6 million in the prior quarter.
- Over five years, Total Debt peaked at $213.5 million in Q1 2026 and troughed at $67.0 million in Q1 2022.
- A 5-year average of $158.3 million and a median of $190.3 million in 2023 frame the typical range for Total Debt.
- The sharpest annual moves came in 2023 and 2025: Total Debt soared 88.75% in 2023, then decreased 3.32% in 2025.
- Over 5 years, Total Debt stood at $100.8 million in 2022, then jumped by 88.75% to $190.3 million in 2023, then grew by 5.23% to $200.2 million in 2024, then grew by 4.16% to $208.6 million in 2025, then gained by 2.35% to $213.5 million in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $213.5 million, $208.6 million, and $196.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 213.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 213.94 Mn |
| Mar 31, 2026 | 213.47 Mn |
| Dec 31, 2025 | 208.56 Mn |
| Sep 30, 2025 | 196.08 Mn |
| Jun 30, 2025 | 190.61 Mn |
| Mar 31, 2025 | 190.58 Mn |
| Dec 31, 2024 | 200.23 Mn |
| Sep 30, 2024 | 189.53 Mn |
| Jun 30, 2024 | 194.29 Mn |
| Mar 31, 2024 | 197.12 Mn |
| Dec 31, 2023 | 190.28 Mn |
| Sep 30, 2023 | 153.34 Mn |
| Jun 30, 2023 | 103.90 Mn |
| Mar 31, 2023 | 104.53 Mn |
| Dec 31, 2022 | 100.81 Mn |
| Sep 30, 2022 | 106.73 Mn |
| Jun 30, 2022 | 83.87 Mn |
| Mar 31, 2022 | 67.04 Mn |
| Dec 31, 2021 | 66.16 Mn |
| Dec 31, 2020 | 63.62 Mn |